In October, due to demand from existing healthcare partners, CTS began testing blood donors for antibody to Babesia microti under an Investigational New Drug exemption as a release test.
CTS embraces a company-wide operational excellence initiative designed to change the culture to enha...
CTS transitioned all 6 CTS labs from an investigational new drug (IND) to a licensed Zika test, and ...
In January, CTS is incorporated as a non-profit organization owned by Vitalant and OneBlood (formerl...
In August CTS begins source plasma testing as a new line of business to one of the largest plasma fr...
In August, the CTS Tampa lab transitioned to the same laboratory information systems (LIS) as the Da...
In April, CTS becomes the first blood donor testing organization in the US to implement Zika testing...